admin – Page 2284 – Get News Story

Recurrent or Metastatic Head and Neck cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Recurrent or Metastatic Head and Neck cancer Pipeline Insight 2025” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Recurrent or Metastatic Head and Neck cancer pipeline landscape. It covers the Recurrent or Metastatic Head and Neck Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Recurrent or Metastatic Head and Neck Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Recurrent or Metastatic Head and Neck Cancer Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Recurrent or Metastatic Head and Neck Cancer Pipeline Outlook

Key Takeaways from the Recurrent or Metastatic Head and Neck Cancer Pipeline Report

On 19 August 2025, Bicara Therapeutics announced a study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
On 17 August 2025, Exelixis conducted a Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with programmed death-ligand 1 (PD-L1) positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.
DelveInsight’s Recurrent or Metastatic Head and Neck Cancer pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Recurrent or Metastatic Head and Neck Cancer treatment.
The leading Recurrent or Metastatic Head and Neck Cancer Companies such as Eisai Co Ltd, Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, Cue Biopharma, AbbVie and others.
Promising Recurrent or Metastatic Head and Neck Cancer Therapies such as docetaxel (XRP6976), cisplatin, 5-fluorouracil (5-FU), Pemetrexed, Cetuximab, Carboplatin, and others.

Discover how the Recurrent or Metastatic Head and Neck Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth pipeline Analysis for a closer look at promising breakthroughs @ Recurrent or Metastatic Head and Neck Cancer Clinical Trials and Studies

Recurrent or Metastatic Head and Neck Cancer Emerging Drugs Profile

Xevinapant: Merck

Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care. Merck gains exclusive global development and commercialization rights; Debiopharm to receive € 188 million upfront and up to € 710 million in regulatory and commercial milestones, as well as royalty payments

SI B001: Sichuan Baili Pharmaceutical

SI B001 is a bispecific antibody designed with the proprietary platform technology developed by Baili and SystImmune. It can bind to EGFR and HER3, and simultaneously inhibits the ligand induced EGFR×EGFR homodimers, the formation of EGFR×HER3 heterodimers and the activation of its downstreamsignal pathway. SI-B001 can also induce endocytosis of EGFR and HER3, anddown-regulate the levels of EGFR and HER3 tumor cells. In preclinical studies, SI-B001 has demonstrated superior tumor killing activities. SI-B001 Phase I trials have shown good safety and preliminary efficacy.

The Recurrent or Metastatic Head and Neck Cancer pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Recurrent or Metastatic Head and Neck Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Recurrent or Metastatic Head and Neck Cancer Treatment.
Recurrent or Metastatic Head and Neck Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Recurrent or Metastatic Head and Neck Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Recurrent or Metastatic Head and Neck Cancer market.

Get a detailed analysis of the latest innovations in the Recurrent or Metastatic Head and Neck Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Recurrent or Metastatic Head and Neck Cancer Unmet Needs

Recurrent or Metastatic Head and Neck Cancer Companies

Eisai Co Ltd, Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, Cue Biopharma, AbbVie and others.

Recurrent or Metastatic Head and Neck cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous

Recurrent or Metastatic Head and Neck Cancer Products have been categorized under various Molecule types such as

Small molecule
Cell Therapy
Peptides
Polymer
Small molecule
Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Recurrent or Metastatic Head and Neck Cancer Therapies and key developments @ Recurrent or Metastatic Head and Neck Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Recurrent or Metastatic Head and Neck Cancer Pipeline Report

Coverage- Global
Recurrent or Metastatic Head and Neck Cancer Companies- Eisai Co Ltd, Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, Cue Biopharma, AbbVie and others.
Recurrent or Metastatic Head and Neck Cancer Therapies- docetaxel (XRP6976), cisplatin, 5-fluorouracil (5-FU), Pemetrexed, Cetuximab, Carboplatin, and others.
Recurrent or Metastatic Head and Neck Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Recurrent or Metastatic Head and Neck Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Recurrent or Metastatic Head and Neck Cancer drug development? Find out in DelveInsight’s exclusive pipeline Report—access it now! @ Recurrent or Metastatic Head and Neck Cancer Emerging Drugs and Major Companies

Table of Content

Introduction
Executive Summary
Recurrent or Metastatic Head and Neck cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Recurrent or Metastatic Head and Neck cancer– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Lenvatinib: Eisai Co
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
SI B001: Sichuan Baili Pharmaceutical
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Revdofilimab: AbbVie
Drug profiles in the detailed report…..
Early Stage Products (Preclinical)
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Recurrent or Metastatic Head and Neck cancer Key Companies
Recurrent or Metastatic Head and Neck cancer Key Products
Recurrent or Metastatic Head and Neck cancer- Unmet Needs
Recurrent or Metastatic Head and Neck cancer- Market Drivers and Barriers
Recurrent or Metastatic Head and Neck cancer- Future Perspectives and Conclusion
Recurrent or Metastatic Head and Neck cancer Analyst Views
Recurrent or Metastatic Head and Neck cancer Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Recurrent or Metastatic Head and Neck cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Advanced Kidney Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Advanced Kidney Cancer Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Advanced Kidney Cancer pipeline landscape. It covers the Advanced Kidney Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Kidney Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Advanced Kidney Cancer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Advanced Kidney Cancer Pipeline Outlook

Key Takeaways from the Advanced Kidney Cancer Pipeline Report

On 17 August 2025, M.D. Anderson Cancer Center announced a Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma. Primary Objectives To determine the efficacy of objective response rate (ORR) and 24-week disease control rate (DCR), per RECIST 1.1, of ivonescimab monotherapy in participants with locally advanced or metastatic renal cell carcinoma with a clear cell component who had progression on at least one prior line of therapy.
On 15 August 2025, Hoffmann-La Roche conducted a study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).
DelveInsight’s Advanced Kidney Cancer pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Advanced Kidney Cancer treatment.
The leading Advanced Kidney Cancer Companies such as Corcept Therapeutics, Janux Therapeutics, Infinity Pharmaceuticals, Merck Sharp & Dohme, Xencor, Exelixis, X4 Pharmaceuticals, Nykode Therapeutics, Tarus Therapeutics, AstraZeneca, RemeGen, NiKang Therapeutics, NGM Biopharmaceuticals, MedImmune and others.
Promising Advanced Kidney Cancer Pipeline Therapies such as TQB2450, Sunitinib, Anlotinib, epothilone b, HB0025, Ipilimumab, RAD001, Belzutifan, Famitinib, L19IL2, Bevacizumab and others.

Stay ahead with the most recent pipeline outlook for Advanced Kidney Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Advanced Kidney Cancer Treatment Drugs

Advanced Kidney Cancer Emerging Drugs Profile

Savolitinib: AstraZeneca

Savolitinib is an oral, potent, and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations or gene amplification. The drug is currently being evaluated under Phase III clinical trial for the treatment of advanced kidney cancer.

Relatlimab: Bristol-Myers Squibb

Relatlimab is a lymphocyte activation gene-3 (LAG-3) blocking antibody and is expressed in a recombinant CHO cell line. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with advanced kidney cancer.

JANX008: Janux Therapeutics

JANX008 is an EGFR-TRACTr that is designed to overcome CRS and known on-target EGFR healthy tissue toxicities. Epidermal growth factor receptor (EGFR) is a clinically validated target highly expressed on many solid tumors that are being underserved by current therapies. JANX008 targets EGFR for the treatment of multiple solid cancers including, but not limited to, colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). The drug is currently being evaluated under Phase I clinical trial for the treatment of Advanced Kidney Cancer.

The Advanced Kidney Cancer Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Kidney Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Kidney Cancer Treatment.
Advanced Kidney Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Advanced Kidney Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Kidney Cancer market

Explore groundbreaking therapies and clinical trials in the Advanced Kidney Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Advanced Kidney Cancer Drugs

Advanced Kidney Cancer Companies

Corcept Therapeutics, Janux Therapeutics, Infinity Pharmaceuticals, Merck Sharp & Dohme, Xencor, Exelixis, X4 Pharmaceuticals, Nykode Therapeutics, Tarus Therapeutics, AstraZeneca, RemeGen, NiKang Therapeutics, NGM Biopharmaceuticals, MedImmune and others.

Advanced Kidney Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Advanced Kidney Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Unveil the future of Advanced Kidney Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Advanced Kidney Cancer Market Drivers and Barriers

Scope of the Advanced Kidney Cancer Pipeline Report

Coverage- Global
Advanced Kidney Cancer Companies- Corcept Therapeutics, Janux Therapeutics, Infinity Pharmaceuticals, Merck Sharp & Dohme, Xencor, Exelixis, X4 Pharmaceuticals, Nykode Therapeutics, Tarus Therapeutics, AstraZeneca, RemeGen, NiKang Therapeutics, NGM Biopharmaceuticals, MedImmune and others.
Advanced Kidney Cancer Pipeline Therapies- TQB2450, Sunitinib, Anlotinib, epothilone b, HB0025, Ipilimumab, RAD001, Belzutifan, Famitinib, L19IL2, Bevacizumab and others.
Advanced Kidney Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Advanced Kidney Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Advanced Kidney Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Advanced Kidney Cancer Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Advanced Kidney Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Advanced Kidney Cancer– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Savolitinib: AstraZeneca
Mid Stage Products (Phase II)
Relatlimab: Bristol-Myers Squibb
Early Stage Products (Phase I)
JANX008: Janux Therapeutics
Preclinical and Discovery Stage Products
Drug name: Company name
Inactive Products
Advanced Kidney Cancer Key Companies
Advanced Kidney Cancer Key Products
Advanced Kidney Cancer- Unmet Needs
Advanced Kidney Cancer- Market Drivers and Barriers
Advanced Kidney Cancer- Future Perspectives and Conclusion
Advanced Kidney Cancer Analyst Views
Advanced Kidney Cancer Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Kidney Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Hereditary Angioedema Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Hereditary Angioedema Pipeline Insight, 2025,” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in Hereditary Angioedema pipeline landscape. It covers the Hereditary Angioedema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hereditary Angioedema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Hereditary Angioedema Pipeline. Dive into DelveInsight’s comprehensive report today! @ Hereditary Angioedema Pipeline Outlook

Key Takeaways from the Hereditary Angioedema Pipeline Report

On 19 August 2025, CSL Behring announced a phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC).
DelveInsight’s Hereditary Angioedema pipeline report depicts a robust space with 20+ active players working to develop 30+ pipeline therapies for Hereditary Angioedema treatment.
The leading Hereditary Angioedema Companies such as Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., and Intellia Therapeutics and others.
Promising Hereditary Angioedema Pipeline Therapies such as NTLA-2002, Donidalorsen, STAR-0215, Garadacimab, TAK-743 300 mg, ADX-324, CSL312, TAK-667, Lanadelumab, KVD900 and others.

Stay ahead with the most recent pipeline outlook for Hereditary Angioedema. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hereditary Angioedema Treatment Drugs

Hereditary Angioedema Emerging Drugs Profile

KVD900: KalVista Pharmaceuticals

KVD900 is a candidate from our oral portfolio of plasma kallikrein inhibitors. It exhibits high solubility and high permeability and is uniquely suited for on-demand treatment of HAE attacks, with rapid uptake into the plasma and high plasma concentrations. Data in phase II clinical trial for KVD900 is anticipated in the fourth quarter of 2020.Currently the drug is in Phase III stage of development for the treatment of Hereditary angioedema.

PHA121: Pharvaris

PHA121 is a novel small molecule with drug-like properties. In preclinical studies, PHA121 demonstrates highly potent and selective competitive antagonism of the B2 receptor, and shows rapid and potent activity on oral dosing in a bradykinin-mediated disease model. It is currently in phase II stage of development.

BMN 331: BioMarin Pharmaceutical

BMN 331 is a gene therapy product candidate for HAE. It is currently in Phase I stage of development.

The Hereditary Angioedema Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Hereditary Angioedema with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hereditary Angioedema Treatment.
Hereditary Angioedema Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hereditary Angioedema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hereditary Angioedema market

Explore groundbreaking therapies and clinical trials in the Hereditary Angioedema Pipeline. Access DelveInsight’s detailed report now! @ New Hereditary Angioedema Drugs

Hereditary Angioedema Companies

Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., and Intellia Therapeutics and others.

Hereditary angioedema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion
Intradermal
Intramuscular
Intranasal
Intravenous
Oral
Parenteral
Subcutaneous
Topical

Hereditary Angioedema Products have been categorized under various Molecule types such as

Gene therapies
Small molecule
Vaccines
Polymers
Peptides
Monoclonal antibodies

Unveil the future of Hereditary Angioedema Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Hereditary Angioedema Market Drivers and Barriers

Scope of the Hereditary Angioedema Pipeline Report

Coverage- Global
Hereditary Angioedema Companies- Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., and Intellia Therapeutics and others.
Hereditary Angioedema Pipeline Therapies- NTLA-2002, Donidalorsen, STAR-0215, Garadacimab, TAK-743 300 mg, ADX-324, CSL312, TAK-667, Lanadelumab, KVD900 and others.
Hereditary Angioedema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hereditary Angioedema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Hereditary Angioedema Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Hereditary Angioedema Companies, Key Products and Unmet Needs

Table of Contents

Introduction
Executive Summary
Hereditary angioedema: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hereditary angioedema – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Hereditary angioedema Collaboration Deals
Late Stage Products (Phase III and NDA)
KVD900: KalVista Pharmaceuticals
Mid Stage Products (Phase II)
PHA121: Pharvaris
Early Stage Products (Phase I)
BMN 331: BioMarin Pharmaceutical
Pre-clinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
Hereditary angioedema Key Companies
Hereditary angioedema Key Products
Hereditary angioedema- Unmet Needs
Hereditary angioedema- Market Drivers and Barriers
Hereditary angioedema- Future Perspectives and Conclusion
Hereditary angioedema Analyst Views
Hereditary angioedema Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hereditary Angioedema Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Immune Thrombocytopenia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Immune Thrombocytopenia Pipeline Insight, 2025,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Immune Thrombocytopenia (ITP) pipeline landscape. It covers the Immune Thrombocytopenia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Immune Thrombocytopenia pipeline On 22 August 2025, Novartis Pharmaceuticals announced a study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ≥30 G/L in adult participants with primary ITP.

Discover the latest drugs and treatment options in the Immune Thrombocytopenia Pipeline. Dive into DelveInsight’s comprehensive report today! @ Immune Thrombocytopenia Pipeline Outlook

Key Takeaways from the Immune Thrombocytopenia Pipeline Report

On 22 August 2025, Memorial Sloan Kettering Cancer Center conducted a study is to see if the study drug, romiplostim, helps low platelet count caused by standard chemotherapy treatment for lymphoma. This study will also look at whether romiplostim can prevent the need for chemotherapy dose delays, chemotherapy dose reductions, and platelet transfusions. In addition, we will determine how safe it is to give romiplostim to people with lymphoma who have low platelet count from chemotherapy.
On 19 August 2025, Kedrion S.p.A. organized a study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP.therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight’s Immune Thrombocytopenia pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Immune Thrombocytopenia treatment.
The leading Immune Thrombocytopenia Companies such as Corcept Therapeutics, UCB, arGEN-X, HanAll Biopharma/Immunovant, Momenta Pharmaceuticals, Principia Biopharma, Hutchison MediPharma, Cour Pharmaceutical Development and others.
Promising Immune Thrombocytopenia Pipeline Therapies such as Huaiqihuang Granule, Avatrombopag, BT595, Romiplostim, Hetrombopag, Rilzabrutinib, SKI-O-703, Eltrombopag, TQB3473 Tablets, and others.

Stay ahead with the most recent pipeline outlook for Immune Thrombocytopenia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Immune Thrombocytopenia Treatment Drugs

Immune Thrombocytopenia Emerging Drugs Profile

Rozanolixizumab (UCB7665): UCB

Rozanolixizumab humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P). By blocking IgG recycling, this subcutaneously infused monoclonal antibody aims to improve the course of immunoglobulin G (IgG)-mediated autoimmune diseases by reducing pathogenic autoantibody levels. Rozanolixizumab, an investigational monoclonal antibody, was granted orphan drug designation for the treatment of ITP by the US Food and Drug Administration on 30 April 2018 and by the European Commission on 11 January 2019. The drug is in Phase III clinical studies for the treatment of idiopathic thrombocytopenic purpura, myasthenia gravis and in Phase II clinical studies for chronic inflammatory demyelinating polyradiculoneuropathy and encephalitis.

Efgartigimod: arGEN-X

Efgartigimod is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). Efgartigimod is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, IgG autoantibodies, where a severe unmet medical need exists. The drug is in registration phase for myasthenia gravis and in Phase III clinical studies for Primary Immune Thrombocytopenia (ITP), chronic inflammatory demyelinating polyradiculoneuropathy, and Pemphigus vulgaris.

The Immune Thrombocytopenia Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Immune Thrombocytopenia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Immune Thrombocytopenia Treatment.
Immune Thrombocytopenia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Immune Thrombocytopenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Immune Thrombocytopenia market

Explore groundbreaking therapies and clinical trials in the Immune Thrombocytopenia Pipeline. Access DelveInsight’s detailed report now! @ New Immune Thrombocytopenia Drugs

Immune Thrombocytopenia Companies

Corcept Therapeutics, UCB, arGEN-X, HanAll Biopharma/Immunovant, Momenta Pharmaceuticals, Principia Biopharma, Hutchison MediPharma, Cour Pharmaceutical Development and others.

Immune thrombocytopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravitreal
Subretinal
Topical

Immune Thrombocytopenia Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Unveil the future of Immune Thrombocytopenia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Immune Thrombocytopenia Market Drivers and Barriers

Scope of the Immune Thrombocytopenia Pipeline Report

Coverage- Global
Immune Thrombocytopenia Companies- Corcept Therapeutics, UCB, arGEN-X, HanAll Biopharma/Immunovant, Momenta Pharmaceuticals, Principia Biopharma, Hutchison MediPharma, Cour Pharmaceutical Development and others.
Immune Thrombocytopenia Pipeline Therapies- Huaiqihuang Granule, Avatrombopag, BT595, Romiplostim, Hetrombopag, Rilzabrutinib, SKI-O-703, Eltrombopag, TQB3473 Tablets, and others.
Immune Thrombocytopenia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Immune Thrombocytopenia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Immune Thrombocytopenia Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Immune Thrombocytopenia Companies, Key Products and Unmet Needs

Table of Contents

Introduction
Executive Summary
Immune thrombocytopenia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Immune thrombocytopenia – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Rozanolixizumab (UCB7665): UCB
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug Name: Company Name
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug Name: Company Name
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Drug Name: Company Name
Inactive Products
Immune thrombocytopenia Key Companies
Immune thrombocytopenia Key Products
Immune thrombocytopenia- Unmet Needs
Immune thrombocytopenia- Market Drivers and Barriers
Immune thrombocytopenia- Future Perspectives and Conclusion
Immune thrombocytopenia Analyst Views
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Immune Thrombocytopenia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Usemultiplier Publishes Review-Based Analysis on Whether Deel Is the Right Fit for Global Employers

Global hiring is no longer limited to enterprises with massive legal teams. Even small and mid-sized companies now build distributed teams using digital tools. But one challenge stays constant, how do you employ people legally in a country where you don’t have an office? That’s where Employer of Record (EOR) platforms come into the picture.

EOR services act as a bridge between global employers and local compliance. They help businesses onboard full-time staff in other countries without opening an overseas entity. The provider becomes the legal employer, handling taxes, benefits, payroll, and contracts while you manage the day-to-day tasks. Deel is one such platform that claims to simplify this process. But how well does it actually perform?

This review-based guide breaks down key takeaways from Deel reviews, highlights features, and explores whether it’s a solid fit, or if employers should consider alternatives.

What Global Employers Expect from EOR Services

Before looking at Deel specifically, it helps to define what most businesses need from an employer of record service:

Quick onboarding across multiple geographies
Legal compliance with local labor laws
Payroll processing in multiple currencies
Clear contracts in local languages
Tax filing and benefits management
Employee support for local issues

If any of these fail, the business risks fines, delays, or employee dissatisfaction. That’s why review-based analysis matters more than a simple feature checklist.

Deel Reviews: Common Themes from Users

Across platforms like G2, Capterra, and Trustpilot, Deel receives mixed reviews, mostly positive for usability, but concerns appear in consistency.

What users like:

Easy user interface
Transparent contract generation
Speedy onboarding in many countries
Access to contractor and full-time models

Common drawbacks:

Limited in-country legal presence in some markets
Delays in local response and issue resolution
Generic benefit packages in less-prioritized countries

Some users mention that Deel operates through third-party partners in countries where it doesn’t have its own legal entity. While this isn’t a dealbreaker, it can affect the level of control and compliance assurance in countries with strict labor laws.

Where Deel Fits Well

For startups expanding to familiar markets like the U.S., U.K., or Australia, Deel performs efficiently. Its dashboard is user-friendly and automates many admin tasks. It works well for contractor-first teams or companies looking to test markets with virtual employees.

The Pay-as-you-go (PAYG) contractor model is another plus. Employers can quickly add or remove freelancers without long-term commitments. Deel also supports crypto payroll, which appeals to newer companies and tech talent.

Where It May Not Be Ideal

Businesses needing deep local expertise, for example, tailored healthcare plans or industry-specific benefits, might find Deel lacking. This is especially true in regions like Southeast Asia, South America, or Eastern Europe, where laws shift frequently.

Another gap that some Deel reviews mention is invoicing or salary delays, especially during cross-border holidays or tax seasons. For roles that involve sensitive client work, these delays can hurt trust.

For larger employers, data visibility also matters. Some Deel users report that reporting tools aren’t detailed enough for managing cost centers or multi-country payroll analysis.

10 Features You Should Consider in an EOR Provider

Instead of choosing by name alone, here’s what global employers should prioritize:

Local entity ownership (not just third-party agents)
Fast onboarding time (under 3 days preferred)
Country-specific benefits options
Transparent fee structure
Real-time support availability
Local contract templates with legal compliance
Support for both contractors and full-time employees
Data and payroll reporting tools
Multilingual documentation
History of user satisfaction from other global teams

These features aren’t nice-to-haves, they’re necessary for scale and compliance. Missing even one can create hiring roadblocks in key regions.

Trusted Alternatives to Consider

If Deel doesn’t match your needs, there are other EORs that offer stronger in-country presence or better customer support. That brings us to a strong alternative many global employers now rely on.

Why Multiplier Is a Strong Alternative to Deel

Multiplier has been gaining attention from global employers for its solid legal setup and onboarding speed. The platform operates in 150+ countries, handles payroll in 120+ currencies, and supports crypto payouts as well.

Unlike platforms that rely heavily on third-party agents, Multiplier owns in-country entities, especially in Asia-Pacific, where compliance demands are stricter. That reduces delays and increases control over employee lifecycle management.

It also provides:

Contract generation in multiple languages
Detailed reporting tools for finance and HR teams
Custom benefits packages based on local labor markets
Cost savings up to 70–90% over setting up local branches
24/7 support with global coverage

With a 4.7/5 rating on G2 and Capterra, and recognition as #1 in implementation in the G2 Fall Report, Multiplier’s real-world performance speaks for itself. Employers looking beyond just automation value the platform’s balance of speed, compliance, and service quality.

Conclusion

Deel has built a reputation for simplifying international hiring, especially for startups and remote-first teams. Its platform automates the basics and offers wide global coverage. But it’s not a one-size-fits-all solution. Companies needing strong local support or tailored compliance may face limitations.

That’s why it’s important to review multiple providers and evaluate based on needs like local ownership, compliance risk, reporting, and employee support.

Global hiring isn’t just a checkbox on a growth strategy, it’s a long-term investment. Multiplier gives employers a broader scope of control, strong legal presence, and trusted onboarding experiences. As EOR competition grows, choosing a solution built for your expansion goals is more important than ever.

Media Contact
Company Name: Multiplier
Contact Person: Mira
Email: Send Email
Country: United States
Website: https://www.usemultiplier.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Usemultiplier Publishes Review-Based Analysis on Whether Deel Is the Right Fit for Global Employers

Travel Experts Reveal the Only Way to Travel in Luxury to Antarctica

Antarctica remains one of the most remote and pristine destinations on Earth — and now, explorers can discover it in complete luxury.

“I’ve never met anyone who’s returned from Antarctica unchanged,” says polar explorer and adventurer Ben Saunders, standing beside a striking image of himself at the South Pole, flashing two thumbs up. “It’s truly mind-blowing.”

This sentiment is shared by countless travelers who have journeyed to the “white desert.” Being surrounded by nothing but ice, mountains, and fierce polar winds is not only humbling but deeply transformative — a powerful draw for adventurers like Saunders.

A leading authority on polar expeditions, Saunders is well-acquainted with the continent. Alongside expedition partner Tarka L’Herpiniere, he became the first to successfully complete the historic and grueling 108-day round trip from Antarctica’s Ross Island to the South Pole — a journey that once defeated the legendary Captain Scott and Sir Ernest Shackleton.

“In Antarctica, there’s magic everywhere you look,” Saunders reflects.

His achievements also include the record for the longest solo Arctic expedition — 2,888 kilometers — and over 6,000 kilometers traveled on skis.

That said, his own tales are far from the picture of a leisurely Antarctic getaway. Over champagne at Bremont’s Mayfair boutique, he recounts hauling 200-kilogram sleds across unchanging landscapes, shedding 20 percent of his body weight, and going more than two months without phone or internet access.

“We once traveled in a straight line for nearly a month without seeing anything,” he recalls. “We crossed valleys that we were fairly certain no human had ever walked through.”

A Rare and Exclusive Destination

Only about 200 people step foot on Antarctica each year — that’s 600 fewer than those who climb Mount Everest annually. This scarcity, combined with the untouched beauty of the land, makes the continent especially appealing to luxury travelers.

Most visitors won’t endure the hardships of glacier hauling and blizzards. Instead, they might arrive aboard a private aircraft, land at the South Pole for photographs, trek across rugged nunataks, and witness colonies of emperor penguins numbering in the hundreds of thousands.

This exclusivity comes at a price: expect to pay between USD $8,000 and $200,000 per person.

“It doesn’t have to be about hardship,” Saunders says. “Antarctica offers pure magic.”

One of our travel correspondents recently reached the South Pole with Antarctic specialists White Desert, who provided insider knowledge on planning an extraordinary journey to the Seventh Continent. It was also listed by travel bloggers as one of the top ten best places to visit by wealthier or more selective adventurers.

According to them, at nearly twice the size of Australia, Antarctica is the most extreme and remote place on Earth — the coldest, driest, windiest continent, and the only one without a permanent human population or a time zone. Here, no reptiles exist, and the icy landscape often feels like another planet entirely.

Though open to tourism, visiting requires specialized ships or planes operated by companies with official permits, equipment, and expertise to handle its harsh conditions. Surprisingly, with the right arrangements, it’s more accessible than many imagine.

Below is your straight-forward guide to making the most of a luxury Antarctic experience.

How to Get to Antarctica

The most popular way to reach Antarctica is via cruise ship from South America, typically departing from Ushuaia, Argentina, or Punta Arenas, Chile. Ushuaia is closer, allowing for less travel time at sea and more time exploring the continent. Cruises, lasting between 9 and 25 days, are often operated by expedition specialists such as Lindblad Expeditions, G Adventures, Hurtigruten Expeditions, and Voyagers Travel.

In recent years, high-end cruise lines like Silversea, Viking, and Hapag-Lloyd have introduced ships purpose-built for polar exploration. Cruises generally visit the Antarctic Peninsula, offering spectacular views of icebergs, glaciers, and wildlife.

One major challenge is crossing the infamous Drake Passage — a two-day journey each way that can bring towering waves and fierce storms. To bypass this, travelers can book a flight-cruise package. These depart from Punta Arenas to King George Island in the South Shetlands, taking just two hours. From there, passengers transfer by Zodiac to an expedition ship, avoiding the roughest seas while still enjoying Antarctic wildlife and scenery.

Antarctica can also be approached from Australia or New Zealand via the Ross Sea, though this journey takes longer, often about a month round trip, and offers fewer departure dates. This route is more of a true expedition — remote, rarely encountering other vessels, and featuring sights such as Mount Erebus, the Ross Ice Shelf, emperor penguins, historic expedition sites, and vast tabular icebergs.

For a truly exclusive experience, some private tours fly guests by private jet from Cape Town, South Africa, directly into the continent’s interior. In about five hours, travelers arrive at the Wolf’s Fang blue ice runway aboard a Gulfstream G550 or Airbus A340, where they can enjoy either a same-day visit or stay at one of the company’s luxury camps. Only a few hundred people each year enjoy this inland access — a sharp contrast to the 120,000 who arrive by cruise.

Best Time to Visit

Travel to Antarctica is only possible during the austral summer (November to March), when ice breaks up enough for ships to navigate. Each part of the season offers unique experiences:

November – The start of the season, with pristine landscapes, towering ice formations, and the first blooms on sub-Antarctic islands.
December & January – The warmest months, with 24-hour daylight and the best opportunities to observe penguins, whales, and other wildlife.
February & March – Fewer visitors and reduced snow cover; whales and seals remain active, but penguin sightings decline.

For White Desert’s flights into Antarctica’s interior, the season is even shorter — mid-November through early February, with December and January being prime months for visiting emperor penguin colonies and the South Pole.

Getting Around & Luxury Camps

Antarctic cruises typically include daily Zodiac excursions, guided hikes, and activities like kayaking alongside marine wildlife. According to social events platform, Bloc.

Private tours, however, offer a completely different experience, taking guests deep inland to towering glaciers and dramatic nunataks. Activities include hiking, mountaineering, abseiling, fat biking, and expeditions to the South Pole and emperor penguin colonies. Guests stay at one of three luxurious camps:

Whichaway – Designer pods overlooking freshwater lakes in the Schirmacher Oasis.
Echo – A futuristic, space-inspired camp surrounded by ice-covered rock formations.
Wolf’s Fang – The adventure base, with heated tents, gourmet dining, and a relaxed lounge atmosphere.

Travel Documents

No visas are required for Antarctica itself, but you’ll need to meet entry requirements for the country from which you depart (Chile, Argentina, New Zealand, Australia, or South Africa). Always check requirements well in advance.

What to Pack

Preparation is key to staying comfortable and safe. Most operators provide detailed packing lists, but essential items include:

SPF 50+ sunscreen (strong UV exposure due to thin ozone layer)
Polarized sunglasses for glare reduction
A neck buff for warmth and wind protection
Merino wool or similar natural fibers for base layers and socks
Health monitoring gadgets and aids such as BURŪV which helps protect your skin from the weather

When it comes to luggage, and you’re trying to keep up with the tradition of luxury in that regard also, it would be best to look towards acquiring quality leather luggage, travel bags, and carry-ons, handmade from the best full-grain vegetable-tanned Italian leather, like some offered by producers such as Von Baer, who takes cognizance of weather-proof requirements. This is necessary because the weather can be very windy sometimes.

Antarctica may be the world’s last great wilderness — but with the right planning, it’s also one of the most exclusive and luxurious travel experiences you can have.

Media Contact
Company Name: SSONNETT Micro-Podcast
Contact Person: David
Email: Send Email
Country: Australia
Website: https://www.kindafrugal.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Travel Experts Reveal the Only Way to Travel in Luxury to Antarctica

Avansaber Launches AI-Powered SAP Utilities ERP to Revolutionize Digital Operations in the Energy Sector

How Artificial Intelligence Accelerates SAP Utilities ERP Projects for Smarter Grid Management and Enhanced Customer Experiences

AUSTIN, TX – August 25, 2025 – As the global energy sector navigates the complexities of decarbonization, grid modernization, and rising customer expectations, the role of technology has never been more critical. At the forefront of this transformation is the integration of Artificial Intelligence (AI) into core operational systems. For utility companies leveraging SAP, AI is no longer a future concept but a present-day reality, revolutionizing how ERP implementation projects deliver value, efficiency, and intelligence.

The migration to SAP S/4HANA Utilities has created a powerful platform for embedding AI and machine learning capabilities directly into the digital core. This shift enables utilities to move beyond traditional process automation and unlock predictive, data-driven operations that enhance everything from asset management to customer engagement.

“For years, ERP systems have been powerful systems of record, but they often operate by looking in the rearview mirror,” states Nikhil Jathar, Co-founder of AvanSaber. “With the infusion of AI, we’re transforming them into forward-looking engines of intelligence.”

Varun Borawake, Co-founder, adds, “This is about more than just automating tasks; it’s about enabling utilities to anticipate grid failures, personalize every customer interaction, and make strategic decisions with a level of foresight that was previously impossible. We’re turning historical data into a utility’s most valuable asset for shaping the future.”

Driving Unprecedented Automation and Efficiency

A primary challenge for utility providers is managing high-volume, repetitive tasks within the meter-to-cash cycle. AI is fundamentally changing this paradigm. By automating crucial ERP processes like meter reading validation, billing, invoicing, and payment processing, AI allows utilities to streamline their end-to-end business operations.

“AI acts as a force multiplier during an SAP ERP implementation,” notes a senior SAP implementation consultant. “Instead of just replacing a legacy system, we are building an intelligent enterprise. With tools like Redwood’s RunMyJobs, we can automate complex workflows within SAP, freeing up valuable human resources to focus on strategic initiatives like innovation and proactive customer service rather than manual data entry and reconciliation.”

Predictive Insights for Superior Asset Management

In an industry where reliability is paramount, managing physical assets effectively is a top priority. With SAP Business AI, utilities are transitioning from reactive to predictive maintenance. AI-driven analytics process vast amounts of sensor data and operational history to forecast equipment failures before they occur.

This capability allows for optimized dispatch planning and proactive maintenance scheduling, which drastically reduces unplanned downtime and extends the life of critical grid components. For example, a leading sustainable energy company, utilizes automated, AI-driven network inspections to streamline maintenance and boost operational efficiency, ensuring a more resilient and reliable grid.

Redefining the Customer Experience

Today’s consumers expect personalized and instantaneous service. AI capabilities integrated within SAP utilities solutions, such as SAP Emarsys Customer Engagement and SAP Service Cloud, are empowering providers to meet and exceed these expectations. Key AI-driven enhancements include:

Intelligent Content Recommendations: Proactively offering customers relevant information on energy savings or new programs.
Automated Case Categorization: Instantly routing customer inquiries to the right department for faster resolution.
Smart, Automated Response Generation: Providing quick, accurate answers to common questions, improving first-contact resolution rates.

Swiss utility Energie Südbayern leverages the SAP Support Assistant for incident optimization, significantly speeding up its customer service processes and improving overall satisfaction.

Ensuring Data Accuracy for Intelligent Operations

The accuracy of operational data is the bedrock of any successful utility. AI algorithms are now being deployed to ensure data integrity across the enterprise by:

Validating millions of meter readings to detect anomalies.
Improving energy forecasting for better load balancing and procurement.
Streamlining bill-to-cash operations to reduce revenue leakage.

This AI-powered validation minimizes the need for manual intervention, enhances financial operations, and makes the mass transaction processing inherent in the utilities industry more efficient and accurate. Industrial services provider IWB in Basel, Switzerland, uses machine learning in its SAP environment for highly accurate solar power forecasting, a testament to AI’s power in managing renewable energy sources.

Generative AI: The Next Frontier in ERP Implementation

Generative AI is further accelerating the pace of innovation within SAP ERP projects. Its applications include:

Automated Integration Development: Generating code and configurations for SAP BTP iFlows, making integrations between systems faster and smarter.
Process Optimization: Predicting bottlenecks and suggesting workflow improvements during the implementation phase.
Enhanced Training and Change Management: Creating tailored training materials and support bots to help employees adapt to new SAP AI features.

Future Outlook: An AI-Driven Industry

The SAP AI roadmap for utilities points toward an even more integrated and intelligent future. As the industry moves toward 2026 and beyond, the focus will be on leveraging AI for greater sustainability, optimizing distributed energy resources (DERs), and ensuring responsible, ethical AI deployment.

For project teams embarking on an SAP S/4HANA Utilities journey, success hinges on embracing AI as a core component of the implementation strategy. The measurable results are clear: significant efficiency gains, double-digit reductions in operational costs, improved customer satisfaction scores, and a stronger foundation for achieving sustainability goals.

The fusion of AI with SAP’s powerful ERP platform is not just an upgrade—it’s a complete operational transformation that is defining the future of the energy and utilities industry.

About AvanSaber

AvanSaber is a pioneering AI technology company providing an innovative SaaS platform built for the energy and utilities sector. We specialize in unlocking the power of artificial intelligence within core ERP systems to help companies modernize operations, redefine customer engagement, and accelerate their strategic objectives. AvanSaber is dedicated to delivering cutting-edge AI solutions that drive measurable business value and a competitive edge in a rapidly evolving industry.

Media Contact
Company Name: Avansaber
Contact Person: Priyanka Patel
Email: Send Email
Country: India
Website: https://www.avansaber.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Avansaber Launches AI-Powered SAP Utilities ERP to Revolutionize Digital Operations in the Energy Sector

Strength Recognized: AIMA Technology’s BIG SUR Series Electric Bikes Win Platinum Award at the 2025 Rome Design Awards

Recently, the highly anticipated 2025 Rome Design Awards winner list was officially announced. The AIMA BIG SUR series electric bikes — the cutting-edge E-bike models from the leading electric two-wheeler brand — stood out from entries worldwide and won the Platinum Award at the 2025 Rome Design Awards for their sleek design and numerous technological innovations.

The Rome Design Awards, hosted by the IAA, aim to honor exceptional accomplishments in the global design community. The awarded works exemplify masterpieces that best meet contemporary requirements while fully satisfying the dual pursuit of aesthetics and practicality. Due to the impact of the energy crisis, the pandemic, congestion and the awakening of global environmental awareness, electric bikes have become a new favorite in the global market over the last few years. In Europe, sports and commuting demands have driven E-bike penetration to approximately 20%, while in the United States, although this demand started later, the market potential is enormous, with a penetration rate of about 4%. Therefore, the demand for E-bikes in both European and American markets is still in its early stages, with vast room for development.

AIMA Technology has developed the BIG SUR series models specifically based on American consumer preferences after an in-depth research into the demands of the mainstream American market. This model integrates human and electric power sources to achieve a hybrid output. Not only does it have higher technological content than traditional two-wheeled electric vehicles, but its unique sports and entertainment attributes, effortless riding experience, and convenient daily commuting method are gradually changing people’s weekend lifestyles. Each new model embodies the core concept of high performance and excellent quality, informed by a deep understanding of the specific needs of different markets.

Thanks to innovative design concepts and outstanding performance, AIMA Technology has demonstrated its leading position in the electric mobility field through cutting-edge products like BIG SUR, achieving precise customization for global consumer needs and continuously energizing the global electric vehicle industry. We have reason to believe that in the future, as the electric vehicle market continues to expand and consumer demand for eco-friendly travel grows, AIMA Technology will push sustainable, fashionable, and high-performance electric mobility experiences to new heights through technical performance development for different usage scenarios, product design styling, and personalized service experiences.

Media Contact
Company Name: AIMA EBIKE
Contact Person: Ian Huang
Email: Send Email
Country: United States
Website: https://www.aimatech.us/

Nomad Internet Launches RecycleNomad.com – The First ISP That Pays Customers to Return Old Modems

Austin, TX – Nomad Internet, the nation’s largest rural wireless internet provider, today announced the launch of RecycleNomad.com, a groundbreaking new initiative that pays customers real cash for returning old Nomad modems. In a first-of-its-kind program for the internet service industry, Nomad is turning equipment returns into an opportunity for customers to earn money, reduce waste, and support rural families who need internet access.

From Fees to Cash Rewards: A Radical Shift

Traditionally, internet providers penalize customers with hefty fees if they fail to return equipment. Nomad is taking the opposite approach by rewarding customers instead.

Through RecycleNomad.com, any customer with an unused Nomad modem can ship it back free of charge using a prepaid label — and receive a $50 Visa® or Mastercard® gift card powered by Tremendous.

“For years, ISPs have charged customers for not returning devices. We’re rewriting the playbook,” said Jaden Garza, CEO of Nomad Internet. “Even if you never want to use Nomad again, we’ll pay you $50 for your old modem. That’s money in your pocket and one less device in a landfill.”

Two Simple Options for Customers

1. Recycle & Get $50:

Send back any old Nomad modem.

Receive a $50 gift card (Visa®, Mastercard®, PayPal, Venmo, or bank transfer).

No obligations. No strings attached.

2. Try Nomad Again & Earn More:

Customers who are willing to test Nomad’s upgraded service will get:

1 Month of Free Service

A $100 gift card after activation and usage

This program is designed to showcase Nomad’s improvements and rebuild trust with former subscribers.

Why RecycleNomad.com Matters

Environmental Impact: Keeps thousands of devices out of landfills and ensures responsible recycling.
Social Impact: Refurbished modems are redistributed to rural families who need affordable, reliable internet access.
Customer Impact: Instead of being penalized, customers are rewarded — creating the first truly positive return experience in the ISP industry.

“RecycleNomad.com isn’t just about recycling hardware,” Garza added. “It’s about showing customers that Nomad has changed. We’ve upgraded our networks, improved speeds, simplified plans, and leveled up customer service. Now we’re inviting people to give us another chance — and we’ll pay them for it.”

A Transformed Nomad Experience

Over the last two years, Nomad Internet has invested heavily in improving its service, making major strides in:

Network Coverage Expansion: Broader rural and remote connectivity across America.
SIM & Technology Upgrades: Smarter, faster devices with seamless activation.
Plan Flexibility: Transparent, affordable plans with no contracts.
Customer Service Overhaul: A new customer-first model with faster response times and proactive support.

RecycleNomad.com is both a sustainability initiative and a bold statement of confidence in these upgrades.

Customer-Centric & Industry-First

Industry analysts note that RecycleNomad.com could set a new precedent for ISPs worldwide. While traditional providers see returns as a cost center, Nomad sees it as a chance to reward customers, reduce waste, and build goodwill.

“This is about trust,” said Garza. “We know not every customer had the best experience in the past. RecycleNomad.com is our way of saying: we value you, we value your time, and we’re willing to put money behind that promise.”

About Nomad Internet

Nomad Internet is the nation’s largest rural wireless internet provider, delivering high-speed connectivity to rural families, travelers, RVers, and underserved communities across America. With innovative solutions like Nomad CashBack and RecycleNomad.com, Nomad is redefining what it means to be a customer-first ISP — one that not only provides internet but actually pays customers back.

For more information, visit www.RecycleNomad.com

Media Contact
Company Name: Nomad Internet
Contact Person: Manish Roshan
Email: Send Email
Phone: +1 281 800 1000
City: Austin
State: Texas
Country: United States
Website: nomadinternet.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Nomad Internet Launches RecycleNomad.com – The First ISP That Pays Customers to Return Old Modems

ODPRN Study Reveals Urgent Need for Action on Drug Addiction in Ontario

Substance abuse has spiralled beyond containment across Ontario. Emergency rooms flood with overdose cases. Families watch loved ones disappear into addiction. The statistics paint a grim reality.

According to the Public Health Agency of Canada research, in 2024, most (80%) of the apparent opioid toxicity deaths in Canada occurred in British Columbia, Alberta, and Ontario. Within the province, more than 2,800 Ontarians died from opioid-related causes in 2021, representing a steady increase over the past decade. Despite this crisis, the Rehab Centre operates beyond capacity as desperate families search for available treatment beds.

What drives this escalation? The answers reveal systemic failures and emerging threats that demand immediate response.

The Deadly Shift to Synthetic Drugs

Street drugs have become exponentially more dangerous. Fentanyl, 50-100 times stronger than morphine, now dominates Ontario’s illegal drug market. Users often consume it unknowingly, mixed into counterfeit pills or cocaine.

Carfentanil presents an even deadlier threat. This elephant tranquillizer is 100 times more potent than fentanyl. A grain-sized amount can kill an adult. Drug dealers mix it into supplies to increase potency and profits, creating unpredictable risks for users.

Stimulant abuse compounds these risks. Cocaine use has surged province-wide, frequently combined with opioids in dangerous cocktails. When users mix uppers and downers, reversing overdoses becomes far more complex. Standard naloxone doses may prove insufficient.

These combinations explain why death rates climb despite expanded access to overdose-reversing medications.

Who Dies and Why

Age patterns reveal troubling trends. Men aged 30-39 represent the largest demographic in overdose emergencies. Yet addiction strikes across all age groups, from teenagers experimenting with pills to seniors managing chronic pain.

The construction industry exemplifies occupational vulnerability. The Ontario Drug Policy Research Network published a report in 2022 that found from 2018 to 2020, nearly one in 13 opioid-related deaths in that province involved someone employed in the construction industry, despite the sector accounting for just 7.2 per cent of Ontario’s employed population.

Physical demands, workplace injuries, and cultural attitudes toward pain management create perfect conditions for prescription drug dependence. Workers often transition from legitimate painkillers to street drugs when prescriptions end.

Marginalized communities bear disproportionate burdens. Indigenous populations, people experiencing homelessness, and those in rural areas face higher overdose rates. Geographic isolation limits access to treatment and emergency response.

Are We Fighting Two Pandemics at Once?

COVID-19 supercharged Ontario’s addiction crisis. Lockdowns isolated vulnerable individuals from support networks. Economic uncertainty increased stress and hopelessness. Treatment centers reduced capacity or closed entirely.

New addiction treatment registrations plummeted 70% during the pandemic’s first month. Existing patients lost access to counselling, group therapy, and medical monitoring. Many relapsed when their support systems disappeared.

Border restrictions disrupted drug trafficking routes, making supplies more unpredictable and contaminated. Dealers cut products with increasingly dangerous substances to maintain profits. Users never knew their consumption risks.

Weekly overdose deaths jumped 35-40% during peak pandemic months. The collision of public health measures with addiction vulnerability created a humanitarian disaster within the larger crisis.

Can Anyone Escape Poverty Without Falling Into Addiction?

Economic desperation fuels substance abuse across Ontario. People with mental health or addiction issues experience poverty at nearly triple the rate of others. Low-income housing remains scarce. Employment discrimination persists.

Social assistance payments keep recipients below survival thresholds. Recipients report choosing between rent, food, and medication. Chronic stress from poverty drives self-medication through drugs and alcohol.

Housing instability worsens these challenges. Without stable addresses, people cannot access treatment programs or maintain recovery. They cycle through emergency shelters, temporary accommodations, and street situations.

Mental health problems intersect with addiction and poverty in destructive patterns. Untreated depression, anxiety, and trauma push people toward substance use. Addiction worsens mental health. Both conditions increase poverty risk.

Is Ontario’s Treatment System Beyond Repair?

Ontario’s addiction treatment infrastructure buckles under demand. Children and youth wait an average of 67 days for counselling. Some regions impose wait times exceeding two years for intensive programs.

Funding allocation reveals misplaced priorities. Addiction and mental health receive 7% of healthcare spending despite causing 11-15% of the province’s disease burden. Emergency departments become default treatment centers for people in crisis.

Geographic disparities create additional barriers. Rural communities often lack specialized services entirely. Urban centers concentrate resources but still cannot meet demand. Transportation costs prevent many from accessing distant treatment facilities.

Program fragmentation complicates care navigation. Separate systems for mental health, addiction, housing, and employment rarely coordinate effectively. People bounce between agencies without receiving integrated support.

Do These Policies Save Lives or Just Delay Deaths?

Naloxone distribution represents Ontario’s most visible harm reduction effort. Pharmacies dispense free overdose-reversal kits. Community organizations train users and families in emergency response techniques.

The province expanded naloxone access in 2018, removing health card requirements and adding nasal spray options. Distribution increased significantly, particularly among people receiving opioid replacement therapy.

Supervised consumption sites operate in nine public health regions. These facilities prevent overdose deaths and connect users with treatment resources. However, they serve only urban areas with concentrated drug activity.

These interventions save lives but focus on immediate needs rather than underlying causes. They respond to emergencies instead of preventing them.

How Can Workplaces Become Part of the Solution?

Research identifies effective strategies Ontario could implement immediately. Medication-assisted treatment shows the highest success rates for opioid addiction. Methadone, buprenorphine, and injectable alternatives reduce cravings and overdose risk.

Housing-first programs demonstrate remarkable effectiveness. Providing stable accommodation without sobriety requirements improves treatment engagement and reduces emergency service use.

Workplace prevention programs could target high-risk industries. Construction companies implementing comprehensive pain management and mental health support report reduced addiction rates among employees.

Early intervention in healthcare settings prevents prescription drug dependence. Training physicians in appropriate opioid prescribing and addiction recognition stops problems before they escalate.

Are We Finally Ready to Act on What We Know?

Ontario faces a choice between continued crisis management and genuine system change. Current approaches treat consequences while overlooking root causes.

These responses require substantial investment in treatment capacity, affordable housing, and mental health services. They also need coordination across healthcare, social services, and criminal justice systems.

Political leadership must prioritize evidence over ideology. Public health approaches work better than punitive measures. Treatment access prevents more crime than incarceration.

Community involvement remains essential. People with lived experience of addiction bring invaluable insights to program design and implementation. Their voices must shape policy decisions.

The crisis will escalate without decisive action. More families will lose loved ones. More communities will struggle with the consequences. But Ontario possesses the knowledge and resources to change direction.

Success means acknowledging that addiction is a health condition, not a moral failing. It requires treating underlying conditions like poverty, trauma, and mental illness. Most importantly, it needs sustained commitment beyond election cycles.

The province stands at a crossroads. One path leads to continued tragedy. The other offers hope through evidence-based reform. The choice seems obvious. The question is whether Ontario will make it.

Media Contact
Company Name: Neamob
Contact Person: Michael Skorupa
Email: Send Email
City: Cobourg
State: ON K9A 3R9
Country: Canada
Website: http://canadiancentreforaddictions.org/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ODPRN Study Reveals Urgent Need for Action on Drug Addiction in Ontario